Utility of serum human epidermal growth factor receptor-2 extracellular domain (HER2 ECD) assessment in patients with advanced or recurrent breast cancer and those who received neoadjuvant therapy

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 2, 2012, Pages 237-240

  Makino, Haruhiko ^a   Iraha, Makiko ^a   Manba, Naoko ^a   Hashidate, Hideki ^a   Shiotani, Motoi ^a  

^a NIIGATA CITY GENERAL HOSPITAL   (Japan)

Author keywords

HER2 ECD (extra cellular domain); HER2 positive breast cancer; Tumor marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; HUMAN; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RECURRENT CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860514398     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792, 2001.
2. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369(9555): 29-36, 2007.
3. Sørensen PD, Jakobsen EH, Langkjer ST, et al: Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 47(9): 1117-1123, 2009.
4. Garoufali A, Kyriakou F, Kountourakis P, et al: Extracellular domain of HER2: A useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON 13(3): 409-413, 2008.
5. Bramwell VHC, Doig GS, Tuck AB, et al: Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 114(3): 503-511, 2009.
6. Ali SM, Carney WP, Esteva FJ, et al: Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 113(6): 1294-1301, 2008.
7. Yamauchi H and Hayes D: HER2 and predicting response to therapy in breast cancer. UpToDate ver. 17.3, 2009.
8. Carney WP: Hidden HER-2/neu-positive breast cancer: how to maximize detection. iDrugs 12(4): 238-242, 2009.
9. Ardavanis A, Kountourakis P, Kyriakou F, et al: Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 13(4): 361-369, 2008.